Skip to content

Psychedelic-assisted therapy: all studies

Page 131 of 294: studies 1,301 to 1,310 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

The Allostatic Reset Model (ARM) of Psychedelic Action

PsyArXiv March 28, 2026 David W. Lawrence, Ari Brouwer, Nicholas Fabiano et al. preprint

Despite being induced by a transient pharmacological exposure, psychedelic experiences can catalyze enduring psychological transformation, presenting a central challenge for understanding the mechanism of action of psychedelic medicines. To address this challenge, the Allostatic Reset Model (ARM) of psychedelic action is proposed, which conceptualizes psychedelic therapeutic effects as a...

Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics

European Archives of Psychiatry and Clinical Neuroscience March 28, 2026 Yves Martins Varela, Vagner Deuel O de Tavares, Luiza Macedo Delgado et al. 1 citation

The use of psychedelics in the treatment of psychopathologies has been expanding, highlighting Psychedelic-Assisted Psychotherapy (PAP) as a promising resource in mental health care. This systematic review investigates. This systematic review investigates whether and how cognitive-behavioral therapies are integrated with psychedelic substances—both classical and atypical—for the treatment of...

Neuroimaging insights from Wistar-Kyoto rats under chronic mild stress: morphological and metabolic brain correlates of treatment-resistant depression.

Scientific Reports March 27, 2026 Gianmauro Palombelli, Valentina Zecca, Marta Boffa et al. 1 citation

Major depressive disorder is highly prevalent and disabling, and many patients do not respond to standard therapies, resulting in treatment-resistant depression (TRD). Progress in TRD requires preclinical models with poor response to conventional treatments. The Wistar-Kyoto rat exposed to chronic mild stress (WKY/CMS) offers a robust paradigm: it shows limited responsiveness to standard...

Psychedelic Experiences and Finitude in Serious Illness: A Qualitative Synthesis

Journal of Pain and Symptom Management March 27, 2026 Ana Cláudia Mesquita Garcia, Geovanna Maria Isidoro, Cremilson de Paula Silva

CONTEXT: People living with serious illness frequently experience intense existential suffering related to awareness of finitude. Psychedelic-assisted therapies have been associated with reductions in death anxiety and existential distress, yet the experiential processes underlying transformations in the relationship with finitude remain insufficiently understood. OBJECTIVES: To synthesize...

DOI: 10.1016/j.jpainsymman.2026.03.012 (opens in new tab) Psilocybin Existentialism Reinterpretation Experiential learning +14

Classic psychedelic medicines for adolescent refractory mental health disease

Journal of Psychedelic Studies March 26, 2026 Aly Shah Aziz

Abstract Adolescent refractory mental health disorders are rising globally, contributing to long-term morbidity and substantial societal burden. Conventional psychotropic medications and psychotherapeutic approaches sometimes fail to provide adequate relief, necessitating an interest in novel investigational interventions. Classic psychedelic compounds—Psilocybin, Lysergic Acid Diethylamide...

Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD).

Brain Sciences March 26, 2026 Piotr Skalski, Katarzyna Pękacka-falkowska, Agnieszka Pluto-Prądzyńska et al.

Background/Objectives: Psilocybin has re-emerged as a promising intervention for neuropsychiatric disorders including major depressive disorder, treatment-resistant depression, anxiety associated with life-threatening illness, obsessive compulsive disorder, and substance use disorders. However, conventional randomized controlled trials (RCTs)-the current gold standard in evidence-based...

DOI: 10.3390/brainsci16040358 (opens in new tab) Full text (opens in new tab) Evidence Psilocybin-assisted therapy pat Psychopharmacology Real-world data rwd

Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies

Frontiers in Cell and Developmental Biology March 25, 2026 Mizuki Yamamoto, Haruka Hirakata, Koji Toda 5 citations

Major depressive disorder is a highly prevalent psychiatric condition that can affect individuals across the lifespan, yet its pathophysiology remains incompletely understood. Classical hypotheses, informed by preclinical and clinical studies, emphasized dysregulated monoaminergic neurotransmission and guided the development of widely prescribed antidepressants, including selective serotonin...

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.

Mini-Reviews in Medicinal Chemistry March 24, 2026 Shivaputra A Patil, Holly C Hunsberger

Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, including psilocybin, are having a...

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations

Expert Opinion on Pharmacotherapy March 24, 2026 Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri et al.

INTRODUCTION: After decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and behavior. AREAS COVERED: This narrative review critically examined the current clinical and regulatory...

DOI: 10.1080/14656566.2026.2654682 (opens in new tab) Clinical trial Medical prescription Medline Equity law +4

Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility

Frontiers in Neuroscience March 23, 2026 Malkanthi Evans, Andrew Charrette

While the limitations of existing treatment options have spurred investigations into the applicability of psychedelic therapies for chronic and treatment-resistant psychological disorders, there remain significant unresolved issues pertaining to how these treatments should be regulated and the implementation of an ethical framework for their widespread delivery in practice. Research...